In vitro and in vivo studies have shown that these inhibitors are effective against tumors with a deletion in the tumor-suppressive locus 11p15.5, where the PTDSS2 gene is located, representing the second isoform of phosphatidylserine synthase [101]. This evidence concerns the gene PTDSS2 and neoplasm.